User profiles for Eshita Khera
 | Eshita KheraPrincipal Scientist, Novartis | Ph.D., University of Michigan Verified email at novartis.com Cited by 578 |
Engineering virus-like particles for antigen and drug delivery
Virus-like particles (VLPs) are nanoscale biological structures consisting of viral proteins
assembled in a morphology that mimic the native virion but do not contain the viral genetic …
assembled in a morphology that mimic the native virion but do not contain the viral genetic …
Increased Tumor Penetration of Single-Domain Antibody–Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Models
A mechanistic study of protein–drug conjugates demonstrates that a lower potency compound
is more effective in vivo than other agents with equal tumor uptake due to improved tissue …
is more effective in vivo than other agents with equal tumor uptake due to improved tissue …
Engineering novel and improved biocatalysts by cell surface display
Biocatalysts, especially enzymes, have the ability to catalyze reactions with high product
selectivity, utilize a broad range of substrates, and maintain activity at low temperature and …
selectivity, utilize a broad range of substrates, and maintain activity at low temperature and …
[HTML][HTML] Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping
E Khera, C Cilliers, MD Smith, ML Ganno, KC Lai… - Neoplasia, 2021 - Elsevier
With the recent approval of 3 new antibody drug conjugates (ADCs) for solid tumors, this
class of drugs is gaining momentum for the targeted treatment of cancer. Despite significant …
class of drugs is gaining momentum for the targeted treatment of cancer. Despite significant …
Pharmacokinetic and immunological considerations for expanding the therapeutic window of next-generation antibody–drug conjugates
E Khera, GM Thurber - BioDrugs, 2018 - Springer
Antibody–drug conjugate (ADC) development has evolved greatly over the last 3 decades,
including the Food and Drug Administration (FDA) approval of several new drugs. However, …
including the Food and Drug Administration (FDA) approval of several new drugs. However, …
Cellular-resolution imaging of bystander payload tissue penetration from antibody-drug conjugates
After several notable clinical failures in early generations, antibody–drug conjugates (ADC)
have made significant gains with seven new FDA approvals within the last 3 years. These …
have made significant gains with seven new FDA approvals within the last 3 years. These …
Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody–Drug Conjugates to Increase In Vivo Efficacy
JF Ponte, L Lanieri, E Khera, R Laleau, O Ab… - Molecular cancer …, 2021 - AACR
Several antibody–drug conjugates (ADC) showing strong clinical responses in solid tumors
target high expression antigens (HER2, TROP2, Nectin-4, and folate receptor alpha/FRα). …
target high expression antigens (HER2, TROP2, Nectin-4, and folate receptor alpha/FRα). …
Computational transport analysis of antibody-drug conjugate bystander effects and payload tumoral distribution: implications for therapy
Antibody drug conjugates (ADCs) have a proven clinical record with four FDA approved
drugs and dozens more in clinical trials. However, a better understanding of the relationship …
drugs and dozens more in clinical trials. However, a better understanding of the relationship …
[HTML][HTML] Oral and subcutaneous administration of a near-infrared fluorescent molecular imaging agent detects inflammation in a mouse model of rheumatoid arthritis
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that causes irreversible
damage to the joints. However, effective drugs exist that can stop disease progression, …
damage to the joints. However, effective drugs exist that can stop disease progression, …
Mechanistically weighted metric to predict in vivo antibody-receptor occupancy: an analytical approach
In situ clinical measurement of receptor occupancy (RO) is challenging, particularly for solid
tumors, necessitating the use of mathematical models that predict tumor receptor occupancy …
tumors, necessitating the use of mathematical models that predict tumor receptor occupancy …